Your fact-checks will appear here
P7C3-A20 has shown efficacy in rodent models of traumatic brain injury.
Clinical research on citicoline (CDP‑choline) has explored a wide range of doses—commonly 250–2,000 mg/day in oral trials—with many neurological studies clustering around 500–1,000 mg/day; benefits re...
A direct search of the recent literature finds no head‑to‑head randomized controlled trials that compare alpha‑GPC (choline alphoscerate) with citicoline (CDP‑choline) specifically in patients diagnos...
No registered clinical trials of P7C3‑A20 are identified in the supplied reporting: the literature supplied documents extensive preclinical work in rodents and nonhuman primates but does not present a...